Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2024 · third_quarter · Medicare/Medicaid
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Client expense: Not reported · Firm income: $100,000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Medicare/Medicaid
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Client expense: Not reported · Firm income: $100,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · first_quarter · Medicare/Medicaid
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Client expense: Not reported · Firm income: $100,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · fourth_quarter · Medicare/Medicaid
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Client expense: Not reported · Firm income: $110,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · third_quarter · Medicare/Medicaid
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Client expense: Not reported · Firm income: $110,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Medicare/Medicaid
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023.
Client expense: Not reported · Firm income: $90,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| TN |
| Mike Crapo | Republican | ID |
| Pete Ricketts | Republican | NE |
| Steve Daines | Republican | MT |
| Ted Cruz | Republican | TX |